4036 related articles for article (PubMed ID: 29500152)
21. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.
Smith R; Strandberg O; Mattsson-Carlgren N; Leuzy A; Palmqvist S; Pontecorvo MJ; Devous MD; Ossenkoppele R; Hansson O
Brain; 2020 Dec; 143(12):3805-3815. PubMed ID: 33439987
[TBL] [Abstract][Full Text] [Related]
22. Effect of Education on Alzheimer's Disease-Related Neuroimaging Biomarkers in Healthy Controls, and Participants with Mild Cognitive Impairment and Alzheimer's Disease: A Cross-Sectional Study.
Wada M; Noda Y; Shinagawa S; Chung JK; Sawada K; Ogyu K; Tarumi R; Tsugawa S; Miyazaki T; Yamagata B; Graff-Guerrero A; Mimura M; Nakajima S;
J Alzheimers Dis; 2018; 63(2):861-869. PubMed ID: 29689728
[TBL] [Abstract][Full Text] [Related]
23. Association between educational attainment and amyloid deposition across the spectrum from normal cognition to dementia: neuroimaging evidence for protection and compensation.
Arenaza-Urquijo EM; Bejanin A; Gonneaud J; Wirth M; La Joie R; Mutlu J; Gaubert M; Landeau B; de la Sayette V; Eustache F; Chételat G
Neurobiol Aging; 2017 Nov; 59():72-79. PubMed ID: 28764930
[TBL] [Abstract][Full Text] [Related]
24. Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer's disease.
Hamelin L; Lagarde J; Dorothée G; Potier MC; Corlier F; Kuhnast B; Caillé F; Dubois B; Fillon L; Chupin M; Bottlaender M; Sarazin M
Brain; 2018 Jun; 141(6):1855-1870. PubMed ID: 29608645
[TBL] [Abstract][Full Text] [Related]
25. APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern.
Risacher SL; Kim S; Nho K; Foroud T; Shen L; Petersen RC; Jack CR; Beckett LA; Aisen PS; Koeppe RA; Jagust WJ; Shaw LM; Trojanowski JQ; Weiner MW; Saykin AJ;
Alzheimers Dement; 2015 Dec; 11(12):1417-1429. PubMed ID: 25960448
[TBL] [Abstract][Full Text] [Related]
26. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
[TBL] [Abstract][Full Text] [Related]
27. Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease.
Mormino EC; Betensky RA; Hedden T; Schultz AP; Ward A; Huijbers W; Rentz DM; Johnson KA; Sperling RA; ; ;
Neurology; 2014 May; 82(20):1760-7. PubMed ID: 24748674
[TBL] [Abstract][Full Text] [Related]
28. Association of β-Amyloid and Apolipoprotein E ε4 With Memory Decline in Preclinical Alzheimer Disease.
Lim YY; Kalinowski P; Pietrzak RH; Laws SM; Burnham SC; Ames D; Villemagne VL; Fowler CJ; Rainey-Smith SR; Martins RN; Rowe CC; Masters CL; Maruff PT
JAMA Neurol; 2018 Apr; 75(4):488-494. PubMed ID: 29356823
[TBL] [Abstract][Full Text] [Related]
29. The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies.
Arenaza-Urquijo EM; Przybelski SA; Lesnick TL; Graff-Radford J; Machulda MM; Knopman DS; Schwarz CG; Lowe VJ; Mielke MM; Petersen RC; Jack CR; Vemuri P
Brain; 2019 Apr; 142(4):1134-1147. PubMed ID: 30851100
[TBL] [Abstract][Full Text] [Related]
30. Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease.
Ossenkoppele R; Lyoo CH; Jester-Broms J; Sudre CH; Cho H; Ryu YH; Choi JY; Smith R; Strandberg O; Palmqvist S; Kramer J; Boxer AL; Gorno-Tempini ML; Miller BL; La Joie R; Rabinovici GD; Hansson O
JAMA Neurol; 2020 May; 77(5):632-642. PubMed ID: 32091549
[TBL] [Abstract][Full Text] [Related]
31. Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer's disease.
Nakamura A; Cuesta P; Fernández A; Arahata Y; Iwata K; Kuratsubo I; Bundo M; Hattori H; Sakurai T; Fukuda K; Washimi Y; Endo H; Takeda A; Diers K; Bajo R; Maestú F; Ito K; Kato T
Brain; 2018 May; 141(5):1470-1485. PubMed ID: 29522156
[TBL] [Abstract][Full Text] [Related]
32. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.
Jack CR; Wiste HJ; Weigand SD; Therneau TM; Knopman DS; Lowe V; Vemuri P; Mielke MM; Roberts RO; Machulda MM; Senjem ML; Gunter JL; Rocca WA; Petersen RC
Lancet Neurol; 2017 Jun; 16(6):435-444. PubMed ID: 28456479
[TBL] [Abstract][Full Text] [Related]
33. Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study.
Morenas-Rodríguez E; Li Y; Nuscher B; Franzmeier N; Xiong C; Suárez-Calvet M; Fagan AM; Schultz S; Gordon BA; Benzinger TLS; Hassenstab J; McDade E; Feederle R; Karch CM; Schlepckow K; Morris JC; Kleinberger G; Nellgard B; Vöglein J; Blennow K; Zetterberg H; Ewers M; Jucker M; Levin J; Bateman RJ; Haass C;
Lancet Neurol; 2022 Apr; 21(4):329-341. PubMed ID: 35305339
[TBL] [Abstract][Full Text] [Related]
34. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
[TBL] [Abstract][Full Text] [Related]
35. Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype.
Espinosa A; Alegret M; Pesini P; Valero S; Lafuente A; Buendía M; San José I; Ibarria M; Tejero MA; Giménez J; Ruiz S; Hernández I; Pujadas F; Martínez-Lage P; Munuera J; Arbizu J; Tárraga L; Hendrix SB; Ruiz A; Becker JT; Landau SM; Sotolongo-Grau O; Sarasa M; Boada M; ;
J Alzheimers Dis; 2017; 57(2):447-459. PubMed ID: 28269787
[TBL] [Abstract][Full Text] [Related]
36. Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's disease.
Papp KV; Amariglio RE; Mormino EC; Hedden T; Dekhytar M; Johnson KA; Sperling RA; Rentz DM
Neuropsychologia; 2015 Jul; 73():169-75. PubMed ID: 26002757
[TBL] [Abstract][Full Text] [Related]
37. Distinct influence of specific versus global connectivity on the different Alzheimer's disease biomarkers.
Mutlu J; Landeau B; Gaubert M; de La Sayette V; Desgranges B; Chételat G
Brain; 2017 Dec; 140(12):3317-3328. PubMed ID: 29194503
[TBL] [Abstract][Full Text] [Related]
38. Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia.
Yew B; Nation DA;
Brain; 2017 Jul; 140(7):1987-2001. PubMed ID: 28575149
[TBL] [Abstract][Full Text] [Related]
39. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.
Förster S; Yousefi BH; Wester HJ; Klupp E; Rominger A; Förstl H; Kurz A; Grimmer T; Drzezga A
Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1927-36. PubMed ID: 22926714
[TBL] [Abstract][Full Text] [Related]
40. Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia.
Chiotis K; Saint-Aubert L; Rodriguez-Vieitez E; Leuzy A; Almkvist O; Savitcheva I; Jonasson M; Lubberink M; Wall A; Antoni G; Nordberg A
Mol Psychiatry; 2018 Jul; 23(7):1666-1673. PubMed ID: 28507319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
